BiotechTube

Dextenza + Prednisolone Acetate

ApprovedCompleted
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Keratoconus, Unstable

Conditions

Keratoconus, Unstable, Collagen Crosslinking, Postoperative Pain

Trial Timeline

Feb 12, 2020 → Apr 5, 2023

NCT ID
NCT04168112

About Dextenza + Prednisolone Acetate

Dextenza + Prednisolone Acetate is a approved stage product being developed by Ocular Therapeutix for Keratoconus, Unstable. The current trial status is completed. This product is registered under clinical trial identifier NCT04168112. Target conditions include Keratoconus, Unstable, Collagen Crosslinking, Postoperative Pain.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT04464629ApprovedTerminated
NCT04168112ApprovedCompleted

Competing Products

7 competing products in Keratoconus, Unstable

See all competitors
ProductCompanyStageHype Score
riboflavin solution + placebo solutionGlaukosPhase 3
74
riboflavin ophthalmic solutionGlaukosPhase 3
74
GLK-221 Ophthalmic Solution + Placebo Ophthalmic SolutionGlaukosPhase 2
49
riboflavin solution + placebo solutionGlaukosPhase 3
74
Riboflavin 5'-PhosphateGlaukosApproved
82
riboflavin solution + placebo solutionGlaukosPhase 3
74
Test Article A + Test Article B + PlaceboGlaukosPhase 3
74

Other Products from Ocular Therapeutix

Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal PulsationApproved
80
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone AcetateApproved
80
Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7%Approved
80
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Approved
80
Dextenza 0.4Mg Ophthalmic InsertApproved
80